1-羟基-1H-吲哚-2-羧酸 | 16264-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-羟基-1H-吲哚-2-羧酸
• 英文名称: 1-hydroxyindole-2-carboxylic acid
• 英文别名: 1-Hydroxy-indol-2-carbonsaeure；N-Hydroxy-2-carboxy-indol；Hydroxy-1-carboxy-2-indol；N-Hydroxylindol-2-carbonsaeure；1-hydroxy-1H-indole-2-carboxylic acid；1-hydroxy-2-indolecarboxylic acid；N-Oxy-indol-α-carbonsaeure；1-Hydroxy-indol-carbonsaeure-(2)；N-Hydroxy-indol-2-carbonsaeure；1-hydroxy-1H-indol-2-carboxylic acid
• CAS: 16264-71-4
• 化学式: C₉H₇NO₃
• 分子量: 177.159
• InChiKey: DPTNMLUPFDKDAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-羟基-1H-吲哚-2-羧酸 在 硫酸 作用下， 生成 1H,1H'-2,2'-Biindolylidene-3,3'-dione
  参考文献：
  名称：

  Reissert, Chemische Berichte, 1897, vol. 30, p. 1040

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基硝基苯 在 tin(II) chloride dihdyrate 、 sodium hydride 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 生成 1-羟基-1H-吲哚-2-羧酸
  参考文献：
  名称：

  Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells

  摘要：

  Highly invasive tumor cells are characterized by a metabolic switch, known as the Warburg effect, from "normal" oxidative phosphorylation to increased glycolysis even under. sufficiently oxygenated conditions. This dependence on glycolysis also confers a growth advantage to cells present in hypoxic regions of the tumor. One of the key enzymes involved in glycolysis, the muscle isoform of lactate dehydrogenase (LDH-A), is overexpressed by metastatic cancer cells and is linked to the vitality of tumors in hypoxia. This enzyme may be considered as a potential target for new anticancer agents, since its inhibition cuts cancer energetic and anabolic supply, thus reducing the metastatic and invasive potential of cancer cells. We have discovered new and efficient N-hydroxyindole-based inhibitors of LDH-A, which are isoform-selective (over LDH-B) and competitive with both the substrate (pyruvate) and the cofactor (NADH). The antiproliferative activity of these compounds was confirmed on a series of cancer cell lines, and they proved to be particularly effective under hypoxic conditions. Moreover, NMR experiments showed that these compounds are able to reduce the glucose-to-lactate conversion inside the cell.

  DOI：

  10.1021/jm101007q

文献信息

• [EN] INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH)<br/>[FR] INHIBITEURS DE DÉRIVÉS D'INDOLE DE L'ENZYME LACTATE DÉHYDROGÉNASE (LDH)
  申请人：UNIV PISA

  公开号：WO2013092753A1

  公开（公告）日：2013-06-27

  The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune system cells in asthmatic diseases, in vascular cells in the pulmonary hypertension, in the treatment of chronic back pain or hyperoxaluria, and in the process by which the parasites protozoan causing malaria obtain most of the necessary energy

  本发明涵盖了具有一般式（I）的化合物，能够抑制与肿瘤组织血管生成中涉及的乳酸产生（乳酸）有关的过程，抑制肿瘤细胞的糖酵解代谢过程，抑制哮喘疾病中免疫系统细胞的过程，抑制肺动脉高压中血管细胞的过程，用于治疗慢性背痛或高草酸尿症，并抑制引起疟疾的原虫寄生虫获得大部分必要能量的过程。
• [EN] COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'ENZYME LACTATE DÉSHYDROGÉNASE (LDH) ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS
  申请人：UNIV PISA

  公开号：WO2011054525A1

  公开（公告）日：2011-05-12

  The present invention concerns compounds, some of which are novel, and their pharmaceutical applications. The compounds of the invention inhibit the enzyme lactate dehydrogenase (LDH) involved both in the metabolic process of hypoxic tumour cells, and in the process used by parasitic protozoa that cause malaria to obtain most of the energy they need.

  这项发明涉及化合物，其中一些是新颖的，以及它们的药用应用。该发明的化合物抑制乳酸脱氢酶（LDH）酶，该酶参与低氧肿瘤细胞的代谢过程，以及疟疾引起的寄生原虫利用获取所需大部分能量的过程。
• Novel coupling components
  申请人：Knuebel Georg

  公开号：US20060016024A1

  公开（公告）日：2006-01-26

  Keratinic fibers, especially human hair are dyed by an agent containing a coupling component which is an m-phenylenediamine derivative of the formula wherein R 1 is a C 1-4 alkyl group or a C 1-4 monohydroxy alkyl group, R 2 is a hydrogen atom, a methyl or an ethyl group and each of R 3 and R 4 is independently a branched or linear C 2-6 hydroxyalkyl group, with the proviso that the R 1 O group is in the ortho or meta position to both amino groups; and a cosmetically acceptable carrier. These agents afford desired color nuances in a sufficient intensity and fastness, exhibit good fiber affinity and are safe from a toxicological and dermatological point of view.

  角蛋白纤维，特别是人类头发，通过含有偶合组分的染料剂染色，该偶合组分是公式的m-苯二胺衍生物，其中R1是C1-4烷基或C1-4单羟基烷基，R2是氢原子、甲基或乙基基团，R3和R4各自独立地是支链或线性C2-6羟基烷基，但R1O基团位于两个氨基团的邻位或间位；以及化妆品可接受的载体。这些剂可以提供所需的颜色细微差异，具有足够的强度和牢度，表现出良好的纤维亲和力，并且从毒理学和皮肤学的角度来看是安全的。
• Indoloylguanidine derivatives
  申请人：Sumitomo Pharmaceuticals Co., Ltd.

  公开号：US06248772B1

  公开（公告）日：2001-06-19

  Novel indoloylguanidine derivatives shown by formula (1), wherein R1 represents one or more, the same or different substituent(s) which is selected from the group consisting of a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a halogen atom, nitro group, an acyl group, carboxyl group, an alkoxycarbonyl group, an aromatic group, and a group shown by formula: —OR3, —NR6R7, —SO2NR6R7 or —S(O)nR40; and R2 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, hydroxy group, an alkoxy group or a group shown by formula: —CH2R20; and which inhibit the Na+/H+ exchanger activity and are useful for the treatment and prevention of a disease caused by increased Na+/H+ exchanger activity, such as hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, disorders associated with ischemia or ischemic reperfusion, cerebro-ischemic disorders; or diseases caused by excessive cell proliferation.

  化合物式（1）所示的新型吲哚基胍衍生物，其中R1表示一个或多个相同或不同的取代基，选自以下组成的群体：氢原子、烷基、取代烷基、烯基、炔基、环烷基、卤素原子、硝基、酰基、羧基、烷氧羰基、芳香基和由式子—OR3、—NR6R7、—SO2NR6R7或—S(O)nR40表示的基团；R2表示氢原子、烷基、取代烷基、环烷基、羟基、烷氧基或由式子—CH2R20表示的基团；这些化合物抑制Na+/H+交换活性，对于治疗和预防由增加的Na+/H+交换活性引起的疾病，如高血压、心律不齐、心绞痛、心肌肥厚、糖尿病、缺血或缺血再灌注相关的疾病、脑缺血性疾病或由过度细胞增殖引起的疾病有用。
• US6169107
  申请人：——

  公开号：——

  公开（公告）日：——